Literature DB >> 15703418

Myelodysplastic syndromes--coping with ineffective hematopoiesis.

Mario Cazzola1, Luca Malcovati.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15703418     DOI： 10.1056/NEJMp048266

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  80 in total

1.  Withdrawing medically futile treatment.

Authors:  Dianna S Howard; Timothy M Pawlik
Journal:  J Oncol Pract       Date:  2009-07       Impact factor: 3.840

2.  Costs and quality of life in patients with myelodysplastic syndromes.

Authors:  Carlo Lucioni; Carlo Finelli; Silvio Mazzi; Esther N Oliva
Journal:  Am J Blood Res       Date:  2013-08-19

3.  Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM).

Authors:  M G Della Porta; H Tuechler; L Malcovati; J Schanz; G Sanz; G Garcia-Manero; F Solé; J M Bennett; D Bowen; P Fenaux; F Dreyfus; H Kantarjian; A Kuendgen; A Levis; J Cermak; C Fonatsch; M M Le Beau; M L Slovak; O Krieger; M Luebbert; J Maciejewski; S M M Magalhaes; Y Miyazaki; M Pfeilstöcker; M A Sekeres; W R Sperr; R Stauder; S Tauro; P Valent; T Vallespi; A A van de Loosdrecht; U Germing; D Haase; P L Greenberg; M Cazzola
Journal:  Leukemia       Date:  2015-02-27       Impact factor: 11.528

Review 4.  Synthetic and natural iron chelators: therapeutic potential and clinical use.

Authors:  Heather C Hatcher; Ravi N Singh; Frank M Torti; Suzy V Torti
Journal:  Future Med Chem       Date:  2009-12       Impact factor: 3.808

5.  Iron overload may promote alteration of NK cells and hematopoietic stem/progenitor cells by JNK and P38 pathway in myelodysplastic syndromes.

Authors:  Yanni Hua; Chaomeng Wang; Huijuan Jiang; Yihao Wang; Chunyan Liu; Lijuan Li; Hui Liu; Zonghong Shao; Rong Fu
Journal:  Int J Hematol       Date:  2017-04-12       Impact factor: 2.490

Review 6.  New drugs in the treatment of myelodysplastic syndromes: are they changing the role of transfusion support?

Authors:  Alberto Grossi; Giancarlo Maria Liumbruno
Journal:  Blood Transfus       Date:  2008-10       Impact factor: 3.443

7.  Flow cytometry immunophenotyping for diagnosis of myelodysplastic syndrome.

Authors:  Mario Cazzola
Journal:  Haematologica       Date:  2009-08       Impact factor: 9.941

8.  Risk assessment in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms.

Authors:  Mario Cazzola
Journal:  Haematologica       Date:  2011-03       Impact factor: 9.941

9.  Blood transfusions and the subsequent risk of cancers in the United States elderly.

Authors:  Regina Riedl; Eric A Engels; Joan L Warren; Andrea Berghold; Winnie Ricker; Ruth M Pfeiffer
Journal:  Transfusion       Date:  2013-01-16       Impact factor: 3.157

10.  Prognostic impact of pre-transplantation transfusion history and secondary iron overload in patients with myelodysplastic syndrome undergoing allogeneic stem cell transplantation: a GITMO study.

Authors:  Emilio Paolo Alessandrino; Matteo Giovanni Della Porta; Andrea Bacigalupo; Luca Malcovati; Emanuele Angelucci; Maria Teresa Van Lint; Michele Falda; Francesco Onida; Massimo Bernardi; Stefano Guidi; Barbarella Lucarelli; Alessandro Rambaldi; Raffaella Cerretti; Paola Marenco; Pietro Pioltelli; Cristiana Pascutto; Rosi Oneto; Laura Pirolini; Renato Fanin; Alberto Bosi
Journal:  Haematologica       Date:  2009-11-10       Impact factor: 9.941
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.